Doxorubicin-chitin-poly(caprolactone) composite nanogel for drug delivery

被引:33
作者
Arunraj, T. R.
Rejinold, N. Sanoj
Kumar, N. Ashwin
Jayakumar, R. [1 ]
机构
[1] Amrita Vishwa Vidyapeetham Univ, Amrita Inst Med Sci, Amrita Ctr Nanosci & Mol Med, Kochi D 682041, Kerala, India
关键词
Chitin; PCL; Composite nanogels; Cancer nanomedicine; Drug delivery; Lung cancer; NANOPARTICLES; CHITOSAN;
D O I
10.1016/j.ijbiomac.2013.08.013
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
070307 [化学生物学]; 071010 [生物化学与分子生物学];
摘要
In this work, we developed a pH responsive chitin-poly(caprolactone) composite nanogels (chitin-PCL CNGs) system for non-small cell lung cancer (NSCLC). A hydrophilic drug, doxorubicin (Dox) was loaded in Chitin-PCL CNGs (Dox-chitin-PCL CNGs). Both control and drug loaded systems were analyzed by DLS, SEM, FTIR and TG/DTA. The size ranges of the control composite nanogels and their drug loaded counterparts were found to be 70 +/- 20 and 240 +/- 20 nm, respectively. The control chitin-PCL CNGs and Dox-chitin-PCL CNGs showed higher swelling and degradation in acidic pH. Drug entrapment efficiency and in-vitro drug release studies were carried out and showed a higher drug release at acidic pH compared to neutral pH. Cellular internalization of the nanogel systems was confirmed by fluorescent microscopy. Dox-Chitin-PCLCNGs showed dose dependent cytotoxicity toward A549 (adenocarcinomic human alveolar basal epithelial cells) cancer cells. Furthermore, the results of in-vitro hemolytic assay and coagulation assay substantiate the blood compatibility of the system. These results indicate that chitin-PCL CNGs is a novel carrier for delivery of anticancer drugs. (C) 2013 Elsevier B.V. All rights reserved.
引用
收藏
页码:35 / 43
页数:9
相关论文
共 30 条
[1]
Amal E., 2006, J DENT, V34, P784
[2]
Doxil® - The first FDA-approved nano-drug: Lessons learned [J].
Barenholz, Yechezkel .
JOURNAL OF CONTROLLED RELEASE, 2012, 160 (02) :117-134
[3]
In vivo and in vitro anti-cancer activity of thermo-sensitive and photo-crosslinkable doxorubicin hydrogels composed of chitosan-doxorubicin conjugates [J].
Cho, Young Il ;
Park, Shinyoung ;
Jeong, Seo Young ;
Yoo, Hyuk Sang .
EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS, 2009, 73 (01) :59-65
[4]
Detection of Adriamycin-DNA adducts by accelerator mass spectrometry at clinically relevant Adriamycin concentrations [J].
Coldwell, Kate E. ;
Cutts, Suzanne M. ;
Ognibene, Ted J. ;
Henderson, Paul T. ;
Phillips, Don R. .
NUCLEIC ACIDS RESEARCH, 2008, 36 (16)
[6]
Haas J, 2005, AAPS PHARMSCITECH, V6
[7]
The effect of molecular weight on the crystallization kinetics of polycaprolactone [J].
Jenkins, M. J. ;
Harrison, K. L. .
POLYMERS FOR ADVANCED TECHNOLOGIES, 2006, 17 (06) :474-478
[8]
Johnson D H, 1999, Clin Lung Cancer, V1, P34, DOI 10.3816/CLC.1999.n.001
[9]
Doxorubicin loaded PVA coated iron oxide nanoparticles for targeted drug delivery [J].
Kayal, S. ;
Ramanujan, R. V. .
MATERIALS SCIENCE AND ENGINEERING C-MATERIALS FOR BIOLOGICAL APPLICATIONS, 2010, 30 (03) :484-490
[10]
Kumar P.T. Sudheesh, 2011, CARBOHYD POLYM, V49, P20